Advertisement
Research Article

An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers

  • Moran Elishmereni,

    Affiliation: Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel

    X
  • Yuri Kheifetz,

    Affiliation: Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel

    X
  • Henrik Søndergaard,

    Affiliation: Novo Nordisk A/S, Malov, Denmark

    X
  • Rune Viig Overgaard,

    Affiliation: Novo Nordisk A/S, Malov, Denmark

    X
  • Zvia Agur mail

    agur@imbm.org

    Affiliations: Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel, Optimata Ltd., Ramat-Gan, Israel

    X
  • Published: September 29, 2011
  • DOI: 10.1371/journal.pcbi.1002206

About the Authors

Moran Elishmereni, Yuri Kheifetz, Zvia Agur
Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel
Henrik Søndergaard, Rune Viig Overgaard
Novo Nordisk A/S, Malov, Denmark
Zvia Agur
Optimata Ltd., Ramat-Gan, Israel

Corresponding Author

Email: agur@imbm.org

Competing Interests

ME, YK, and ZA have no competing interests. HS and RVO have read the journal's policy and have the following potential conflicts: both authors are employed by Novo Nordisk A/S.

Author Contributions

Conceived and designed the experiments: ME YK HS ZA. Performed the experiments: ME YK HS. Analyzed the data: ME YK HS ZA. Contributed reagents/materials/analysis tools: YK RVO. Wrote the paper: ME RVO ZA.